Vol. 13. Núm. 40.
Páginas 2302-2312 (Octubre 2021)

Actualización
Valvulopatía mitral

Mitral valve disease

X. Cía MendiorozD. de Castro CamposD. Escribano GarcíaJ. Segovia Cubero
Doi : https://10.1016/j.med.2021.09.002
Opciones
Resumen

La valvulopatía mitral constituye una de las principales causas de las enfermedades cardíacas y se encuentra en aumento debido al envejecimiento de la población. Se clasifican en insuficiencia y estenosis mitral en función del tipo de disfunción. La fiebre reumática encabeza las causas de estenosis mitral, aunque la degenerativa continúa incrementándose a consecuencia del aumento de la expectativa de vida de la población. La insuficiencia mitral se clasifica en dos grupos en función de su fisiopatología: la insuficiencia mitral orgánica por afectación primaria del aparato valvular mitral, y la insuficiencia mitral funcional que presenta un mal funcionamiento de la válvula mitral secundario a disfunción y dilatación ventricular sin aparato valvular mitral íntegro. El tratamiento se dirige cada vez más a la conservación de la válvula mitral, intentando evitar el recambio valvular mitral en la medida de lo posible. En la estenosis mitral se aboga por las técnicas percutáneas de valvuloplastia como primera opción, y en la insuficiencia mitral preferiblemente técnicas quirúrgicas de reparación o tratamientos percutáneos en los cuales existen múltiples avances en los últimos años, especialmente en el tratamiento de la insuficiencia funcional.

Palabras clave
Valvulopatía mitral
Estenosis mitral
Insuficiencia mitral
Intervencionismo percutáneo
Abstract

Mitral valve disease is a primary cause of heart disease and is increasing due to population ageing. The disease is classified into mitral valve regurgitation and mitral stenosis depending on the type of dysfunction. Rheumatic fever is the leading cause of mitral stenosis, although degenerative mitral stenosis is on the rise due to the increasing life expectancy of the population. Mitral valve regurgitation is classified into two groups according to its pathophysiology: organic mitral valve regurgitation due to primary involvement of the mitral valve apparatus, and functional mitral valve regurgitation with mitral valve malfunction secondary to ventricular dysfunction and dilatation without an intact mitral valve apparatus. Treatment is increasingly aimed at preserving the mitral valve, attempting as far as possible to avoid mitral valve replacement. Percutaneous valvuloplasty techniques are advocated as the first option in mitral valve stenosis, and surgical repair procedures or percutaneous treatments are preferred in mitral valve regurgitation, in which there have been many advances in recent years, especially in the treatment of functional regurgitation.

Keywords
Mitral valve disease
Mitral valve stenosis
Mitral valve regurgitation
Percutaneous intervention

Identifíquese

¿Aún no es suscriptor de la revista?

Comprar el acceso al artículo

Comprando el artículo el pdf del mismo podrá ser descargado

Teléfono para incidencias

De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h

Llamadas desde España 932 415 960
Llamadas desde fuera de España +34 932 415 960
Bibliografía
[1]
J.P. Dal-Bianco
202110050612161571
, R.A. Levine.
Anatomy of the mitral valve apparatus: role of 2D and 3D echocardiography.
Cardiol Clin., (2013), 31 pp. 151-164
[2]
B. Iung
202110050612161572
, A. Vahanian.
Epidemiology of acquired valvular heart disease.
Can J Cardiol., (2014), 30 pp. 962-970
[3]
P.B. Bertrand
202110050612161573
, C.G. Mihos, E. Yucel.
Mitral annular calcification and calcific mitral stenosis: Therapeutic challenges and considerations.
Curr Treat Options Cardiovasc Med., (2019), 21 pp. 19
[4]
H. Baumgartner
202110050612161574
202110050612161575
, J. Hung, J. Bermejo, J.B. Chambers, A. Evangelista, B.P. Griffin, et al.
Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice.
Eur J Echocardiogr., (2009), 10 pp. 1-25
[5]
C.M. Otto
202110050612161576
202110050612161577
, R.A. Nishimura, R.O. Bonow, B.A. Carabello, J.P. Erwin, 3rd, F. Gentile, et al.
2020 ACC/AHA Guideline for the management of patients with valvular heart disease: Executive summary: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
[6]
H. Baumgartner
202110050612161578
202110050612161579
, V. Falk, J.J. Bax, M. De Bonis, C. Hamm, P.J. Holm, et al.
2017 ESC/EACTS Guidelines for the management of valvular heart disease.
Eur Heart J., (2017), 38 pp. 2739-2791
[7]
G. Reis
2021100506121615710
, M.S. Motta, M.M. Barbosa, W.A. Esteves, S.F. Souza, E.A. Bocchi.
Dobutamine stress echocardiography for noninvasive assessment and risk stratification of patients with rheumatic mitral stenosis.
J Am Coll Cardiol., (2004), 43 pp. 393-401
[8]
J.Y. Kim
2021100506121615711
, S.H. Kim, J.P. Myong, et al.
Outcomes of direct oral anticoagulants in patients with mitral stenosis.
J Am Coll Cardiol., (2019), 73 pp. 1123-1131
[9]
R.A. Meneguz-Moreno
2021100506121615712
, J.R. Costa Jr., N.L. Gomes, S.L.N. Braga, A.I.O. Ramos, Z. Meneghelo, et al.
Very long term follow up after percutaneous balloon mitral valvuloplasty.
JACC Cardiovasc Interv., (2018), 11 pp. 1945-1952
[10]
M. Guerrero
2021100506121615713
, D. Dvir, D. Himbert, M. Urena, M. Eleid, D.D. Wang, et al.
Transcatheter Mitral Valve Replacement in Native Mitral Valve Disease With Severe Mitral Annular Calcification: Results From the First Multicenter Global Registry.
JACC Cardiovasc Interv., (2016), 9 pp. 1361-1371
[11]
J.L. Moya Mur
2021100506121615714
, J.S. Reyes Villanes, A.C.S. Román, A. García Martín, C. Izurieta.
Lesiones de la válvula mitral.
Med [Internet]., (2017), 12 pp. 2345-2356
[12]
P. Lancellotti
2021100506121615715
, L. Moura, L.A. Pierard, E. Agricola, B.A. Popescu, C. Tri- bouilloy, et al.
European association of echocardiography recommendations for the assessment of valvular regurgitation. Part 2: Mitral and tricuspid regurgitation (native valve disease).
Eur J Echocardiogr., (2010), 11 pp. 307-332
[13]
Valvular heart disease. A Companion to Braunwald's Heart Disease, 4a ed, Elsevier Saunders,
[14]
A. Carpentier
2021100506121615716
, S. Chauvaud, J.N. Fabiani, A. Deloche, J. Relland, A. Lessana, et al.
Reconstructive surgery of mitral valve incompetence: ten-year ap praisal.
J Thorac Cardiovasc Surg., (1980), 79 pp. 338-348
[15]
C. Chinchilla
2021100506121615717
, I. Rodríguez-bailón, F. Carrasco.
¿Qué parámetros ecocardiográficos debemos considerar para reparar la válvula mitral? Which echocardiographic parameters should be considered for mitral valve repair?, (2012), 47 pp. 94-98
[16]
D. Stolfo, M. Merlo, B. Pinamonti, S. Poli, M. Gigli, G. Barbati, et al.
Early improvement of functional mitral regurgitation in patients with idiopathic dilated cardiomyopathy.
Am J Cardiol., (2015), 115 pp. 1137-1143
[17]
L.A. Piérard
2021100506121615718
, P. Lancellotti.
The role of ischemic mitral regurgitation in the pathogenesis of acute pulmonary edema.
N Engl J Med., (2004), 351 pp. 1627
[18]
R. Pizarro, O.O. Bazzino, P.F. Oberti, M. Falconi, F. Achilli, A. Arias, et al.
Prospective validation of the prognostic usefulness of brain natriuretic peptide in asymptomatic patients with chronic severe mitral regurgitation.
J Am Coll Cardiol., (2009), 54 pp. 1099-1106
[19]
W.A. Zoghbi
2021100506121615719
, D. Adams, R.O. Bonow, M. Enriquez-Sarano, E. Foster, et al.
Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of echocardiography developed in collaboration with the Society for cardiovascular magnetic resonance.
J Am Soc Echocardiogr., (2017), 30 pp. 303-371
[20]
R.P. Steeds
2021100506121615720
, S.G. Myerson.
Imaging assessment of mitral and aortic regurgitation: current state of the art Education in Heart.
Heart [Internet], (2020),
[21]
M. Garbi
2021100506121615721
, M.J. Monaghan.
Quantitative mitral valve anatomy and plans of this research. pathology.
Echo Res Pract., (2015), 2 pp. R63-R72
[22]
M. Galderisi
2021100506121615722
, B. Cosyns, T. Edvardsen, N. Cardim, V. Delgado, G. Di Salvo, et al.
Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert con sensus document of the European Association of Cardiovascular Imaging.
Eur Heart J Cardiovasc Imaging, (2017), 18 pp. 1301-1310
[23]
R.T. Hahn
2021100506121615723
, T. Abraham, M.S. Adams, C.J. Bruce, K.E. Glas, R.M. Lang, et al.
Guidelines for performing a comprehensive transesophageal echocardiographic examination: Recommendations from the American Society of Echocardiography and the Society of Cardiovascular Anesthesiologists.
J Am Soc Echocardiogr., (2013), 26 pp. 921-964
[24]
J.J. Bax
2021100506121615724
, P. Debonnaire, P. Lancellotti, N. Ajmone Marsan, L.F. Tops, et al.
Transcatheter interventions for mitral regurgitation: multimodality imaging for patient selection and pro cedural guidance.
JACC Cardiovasc Imaging, (2019), 12 pp. 2029-2048
[25]
P. Lancellotti
2021100506121615725
, L. Moura, L.A. Pierard, E. Agricola, B.A. Popescu, C. Tribouilloy, et al.
European Association of Echocar diography recommendations for the assessment of valvular regurgitation. Part 2: mitral and tricuspid regurgitation (native valve disease).
Eur J Echo-cardiogr., (2010), 11 pp. 307-332
[26]
P. Lancellotti
2021100506121615726
, P. Troisfontaines, A.C. Toussaint, L.A. Pierard.
Prognostic importance of exercise-induced changes in mitral regurgitation in patients with chronic ischemic left ventricular dysfunction.
[27]
T. Le Tourneau
2021100506121615727
, M. Richardson, F. Juthier, T. Modine, G. Fayad, A.S. Polge, et al.
Echocardiography predictors and prognostic value of pulmonary artery systolic pressure in chronic organic mitral regurgitation.
Heart., (2010), 96 pp. 1311-1317
[28]
S. Uretsky
2021100506121615728
, E. Argulian, J. Narula, S.D. Wolff.
Use of cardiac magnetic resonance imaging in assessing mitral regurgitation: current evidence.
J Am Coll Cardiol., (2018), 71 pp. 547-563
[29]
P. Blanke
2021100506121615729
, C. Naoum, J. Webb, D. Dvir, R.T. Hahn, P. Grayburn, et al.
Multimodality imaging in the context of transcatheter mitral valve replacement: establishing consensus among modalities and disciplines.
JACC Cardiovasc Imaging., (2015), 8 pp. 1191-1208
[30]
D. Vivas Balcones, J. Higueras Nafría, R. Bover Freire, I. Vilacosta, C. Macaya Miguel.
Procedimientos de actuación en patología cardiovascular.
3a ed., Fundación Médica para la Investigación y Desarrollo Área Cardiovascular, (2018),
[31]
R.M. Suri
2021100506121615730
, J.L. Vanoverschelde, F. Grigioni, H.V. Schaff, C. Tribouilloy, J.F. Avierinos, et al.
Association between early surgical intervention vs watchful waiting and outcomes for mitral regurgitation due to flail mitral valve leaflets.
JAMA., (2013), 310 pp. 609-616
[32]
S. Lazam
2021100506121615731
, J.-L. Vanoverschelde, C. Tribouilloy, F. Grigioni, R.M. Suri, J.F. Avierinos, et al.
Twenty-year outcome after mitral repair versus replacement for severe degenerative mitral regurgitation: analysis of a large, prospective, multicenter, international registry.
Circulation., (2017), 135 pp. 410-422
[33]
J.G.Y. Luc
2021100506121615732
, J.C. Hong, A.W. Cheung, R.C. Cook, P.L. Skarsgard, J. Ye, et al.
The MITRA-FR Trial Vs the COAPT Trial: More Complementary Than Contradictory?.
Ann Thorac Surg., (2019), 108 pp. 965-968
[34]
P. Pibarot
2021100506121615733
, J.G. Dumesnil.
Prosthetic heart valves: selection of the opti- mal prosthesis and long-term management.
Circulation., (2009), 119 pp. 1034-1048
[35]
P. Lancellotti
2021100506121615734
2021100506121615735
, P. Pibarot, J. Chambers, T. Edvardsen, V. Delgado, R. Dulgheru, et al.
Recommendations for the imaging assessment of prosthetic heart valves: a report from the European Association of Cardiovascuar Imaging endorsed by the Chinese Society of Echocardiography, the Inter-American Society of Echocardiography, and the Brazilian Department of Cardiovascular Imaging.
Eur Heart J Cardiovasc Imaging., (2016), 17 pp. 589-636
[36]
A.B. Goldstone
2021100506121615736
, P. Chiu, M. Baiocchi, B. Lingala, W.L. Patrick, M.P. Fischbein, et al.
Mechanical or biologic prostheses for aortic-valve and mitral-valve replacement.
N Engl J Med., (2017), 377 pp. 1847-1857
[37]
M. Özkan
2021100506121615737
, S. Gündüz, O.M. Gürsoy, S. Karakoyun, M.A. Astarcıoğlu, M. Kalçık, et al.
Ultraslow thrombolytic therapy: A novel strategy in the management of Prosthetic MEchanical valve Thrombosis and the prEdictors of outcomE: The Ultra-slow PROMETEE trial.
Am Heart J., (2015), 170 pp. 409-418
[38]
W.A. Zoghbi
2021100506121615738
, F.M. Asch, C. Bruce, L.D. Gillam, P.A. Grayburn, R.T. Hahn, et al.
Guidelines for the evaluation of valvular regurgitation after percutaneous valve repair or replacement: A report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Angiography and Interventions, Japanese Society of Echocardiography, and Society for Cardiovascular Magnetic Resonance.
J Am Soc Echocardiogr., (2019), 32 pp. 431-475